InvestorsHub Logo

H2R

Followers 42
Posts 2159
Boards Moderated 0
Alias Born 07/17/2014

H2R

Re: midastouch017 post# 706

Tuesday, 04/18/2017 8:35:47 AM

Tuesday, April 18, 2017 8:35:47 AM

Post# of 3878
Hi MidasTouch,

This part of the PR highlights how well they keep on executing:

Top-line results from the Phase III study with BEKINDA® 24 mg for acute gastroenteritis and gastritis (the GUARD study) are expected in the second quarter of 2017. In February 2017, RedHill announced that the last patient had completed the treatment course and observation period in the randomized, double-blind, placebo-controlled GUARD study, which treated 320 adults and children over the age of 12 in 29 U.S. clinical sites.



They keep moving along nicely. If positive, the top line results will help with credibility and valuation IMHO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News